Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 4Withdrawn 3Terminated 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 3Neoplasm Metastasis 1Carcinoma 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × futuximab × Clear all
NCT05223673 2024-08-20

COLSTAR

Servier

Phase 3 Terminated
7 enrolled 12 charts
Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT03549338 2020-09-28

Sym004 Versus Futuximab or Modotuximab in Patients With mCRC

Symphogen A/S

Phase 2 Terminated
2 enrolled 9 charts
Gastrointestinal

Carcinoma, Colorectal Neoplasms

NCT02568046 2019-03-26

Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients

Symphogen A/S

Phase 1/2 Terminated
10 enrolled 14 charts
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡